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Introduction:  Growing  evidence  suggests  that  oxidative  stress  (OS)  may  be associated  with  the pathophys-
iology  underlying  schizophrenia  (SZ).  Some  studies  indicate  that  nutritional  supplements  offer  protection
from  OS,  but  there  is no  data  about  the effect  of  a hypocaloric  diet  on  OS  in  this  population.  Therefore,
we  aimed  to study  the  effect  of  a hypocaloric  dietary  intervention  on  OS  in  subjects  with SZ.
Methods: A  cross-sectional  study  of  96  participants  in outpatient  treatment  for  SZ  comprised  patients
separated  into  two  groups:  one  group  of  subjects  followed  a hypocaloric  diet (HD)  program  (n  =  42),
while  the  other  group  followed  a regular  diet  (RD)  with  no  nutritional  restrictions  (n  = 54). The serum
total  radical-trapping  antioxidant  parameter  (TRAP),  total  antioxidant  reactivity  (TAR)  and  thiobarbituric
acid  reactive  species  (TBARS)  levels  were  assessed.
Results: TRAP  levels  were  lower  and  TBARS  levels  were  higher  in the  HD  group  than  in the  RD  group
(p  =  0.022  and  p =  0.023,  respectively).  There  were  no differences  in  TAR  levels  between  the  groups.  Addi-
tionally,  there  was a  positive  correlation  between  TRAP  and  TBARS  levels  after  adjusting  for  BMI  and
clozapine  dose  (partial  correlation  = 0.42, p < 0.001).  There  were  no  correlations  among  the  length  of
illness  or diet  and  the  levels  of  TRAP,  TBARS,  and  TAR.
Conclusions: Subjects  with  SZ  on  a hypocaloric  diet  displayed  different  OS  parameters  than  those  not
following  a HD. Serum  TRAP  levels  were  lower  and  TBARS  levels  were  higher  among  SZ  subjects  with  HD
compared  to  SZ subjects  without  HD.  Lower  TRAP  levels  may  reﬂect  decreased  oxidative  stress,  whereas
higher  TBARS  levels  most  likely  reﬂect  a biochemical  reaction  to the  decreased  TRAP  levels.  Additionally,
TAR  levels  were  similar  between  groups,  suggesting  a  similar  quality  of  antioxidant  defenses,  despite
quantitative  differences  between  the two  dietary  protocols  in  SZ  patients  under  outpatient  care.. Introduction
Many psychiatric disorders, such as schizophrenia (SZ), are
ssociated with increased oxidative stress (OS), obesity, overall
orbidity and increased mortality from cardiovascular disease
CVD) [1,4,11,21,26]. Additionally, growing evidence suggests that
S may  also be associated with the pathophysiology underlying SZ
12,18]. A decrease in the antioxidant defense system during the
arly onset of the ﬁrst psychotic episode in SZ patients was recently
emonstrated [16].
∗ Corresponding author at: Hospital de Clínicas de Porto Alegre, Av Ramiro Barce-
os  2350, Porto Alegre, RS, Brazil. Tel.: +55 51 84296901; fax: +55 51 21018846.
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304-3940     ©  2012 Elsevier Ireland Ltd. 
oi:10.1016/j.neulet.2012.01.060
Open access under the Elsevier OA license.© 2012 Elsevier Ireland Ltd. 
High caloric intake and poor dietary choices are common in SZ
and associated with increased reactive oxygen species [19–21]. Epi-
demiological studies in the general population showed an inverse
correlation between fruit and vegetable intake and CVD, cancer, and
age-related disorders [24]. Other studies show a beneﬁcial effect of
dietary antioxidants in the prevention of OS-related diseases [22].
Some oral supplements, such as vitamins A and C, may  be beneﬁ-
cial in the management of OS [2,5,17]. Nevertheless, no studies have
evaluated the effectiveness of a daily consumption of nutrients on
modulating OS in SZ.
Obesity  and its related medical conditions contribute to an
increased mortality rate and the high healthcare costs associated
Open access under the Elsevier OA license.with SZ [10]. Many of the weight-management strategies used
in the general population may  be applicable to psychiatric pop-
ulations; however, most large-scale weight-loss studies exclude
people with severe mental illness, and no data exists about the
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ffects of these strategies on psychiatric subjects [1]. An interven-
ion using selected dietary products with high levels of antioxidants
ay modulate inﬂammatory processes and OS in healthy, over-
eight subjects [3]. In SZ, a recent report suggests that a hypocaloric
iet (HD) may  modify brain plasticity [8]. However, no studies
ddress the inﬂuence of a HD on the parameters of OS in subjects
ith SZ.
The  aim of this study was to investigate an OS and HD
ntervention in SZ. The OS was assessed in serum by the total antiox-
dant capacity (TAC), which incorporated the total radical-trapping
ntioxidant parameter (TRAP), the total antioxidant reactivity
TAR) levels, and the thiobarbituric acid reactive species (TBARS), an
ndex of cell lipid peroxidation. The nutritional treatment included
 HD program and a recommendation for increasing the intake of
ruits and vegetables to improve the inadequate nutritional choices
ssociated with body mass index increase (BMI) and comorbidities.
. Materials and methods
.1.  Subjects and measurements
We  conducted a cross-sectional study in 96 outpatients with
Z. All subjects were recruited using convenience sampling from
he Schizophrenia Program, Hospital de Clinicas de Porto Alegre,
razil, from January to July 2009. Diagnosis of SZ was established
ccording to the Structured Clinical Interview for DSM-IV-Axis I
isorders (SCID-I).
The  participants were separated into the following two groups
ccording to their diet consumption: (1) subjects following a
ypocaloric diet (HD) treatment (n = 42) and (2) subjects follow-
ng a regular diet (RD) with no nutritional orientation (n = 54). The
atients were administered HD treatment according to medical
ndications that controlled for nutritional intake and antipsychotic-
etabolic side effects. The HD prescription consisted of a low-fat
iet with diary intake of 20–25 kcal/kg/day prescribed by a trained
utritionist with expertise in psychiatric disorders. The HD group
eceived a nutritional orientation designed to reduce sugar and sat-
rated fat intake and to increase fruit and vegetable consumption.
he RD group did not receive any nutritional orientation and did
ot follow any speciﬁc dietary restrictions.
The HD patients followed the dietary prescription for at least six
onths prior to venipuncture to measure oxidative parameters.
he HD treatment consisted of a structured program employing
nthropometric measurements and a clinical interview at each
isit, which included a 24-h dietary recall questionnaire addressing
iet compliance. A trained nutritionist monitored adherence to the
D and reinforced the nutritional orientation once per month over
he total follow-up. Lipid proﬁles and fasting glucose levels were
hecked every six months.
The  clinical evaluation included assessments of the body mass
ndex (BMI), smoking status, arterial blood pressure, physical activ-
ty, glucose levels and cholesterol levels. Metabolic syndrome was
eﬁned according to the Executive Summary of the Third Report of
he National Cholesterol Education Program [7].
All  subjects with SZ had been on typical and atypical antipsy-
hotics for at least ﬁve years. Psychopathology severity was
valuated by the Brief Psychiatric Rating Scale (BPRS). Prior to
nrollment in the study, all participants provided written informed
onsent that was approved by the Ethics Research Committee of
CPA (GPPG #08-436)..2.  Biochemical measurements
Five  milliliters of blood were collected by venipuncture into
 free-anticoagulant vacuum tube. The blood was immediatelyetters 512 (2012) 43– 47
centrifuged at 3000 × g for 5 min, and serum was kept frozen at
−80 ◦C until assayed. OS measures included TBARS, TAR and TRAP.
For the TBARS assessment, the samples were brieﬂy mixed with
0.6 ml  of 10% trichloroacetic acid (TCA) and 0.5 ml  of 0.67% TBA
(4,6-dihydroxypyrimidine-2-thiol). This mixture was  then heated
in a boiling water bath for 25 min, and TBARS were assessed by
absorbance in a spectrophotometer at 532 nm.  The results were
expressed as nmol malondialdehyde equivalents/mg protein. For
the TRAP assessment, the reaction was  initiated by adding lumi-
nol (5-amino-2,3-dihydro-1,4-phthalazinedione, 4 mM),  which
was used as an external probe to monitor radical produc-
tion, and 2,2′-azobis-2-methyl-propionamidine-dihydrochloride
(10 mM),  which served as a free radical source producing per-
oxyl radicals at a constant rate, in glycine buffer (0.1 M,  pH 8.6)
at room temperature. This reaction resulted in a steady lumines-
cence emission (system counts). Sample addition decreases the
luminescence proportionally to its antioxidant potential. Chemi-
luminescence was  read in a liquid luminescence counter as counts
per minute. The luminescence emission was  followed for 40 min
after the addition of the sample (100 g of protein) in a TRAP pro-
tocol, and the area under the curve was quantiﬁed. The area under
the curve obtained from the chemiluminescence values was trans-
formed to percentage values and compared against control values.
In the TAR protocol, the results were expressed as a percentage of
radical production (system counts considered as 100% of radical
production) [6].
2.3.  Statistical analysis
Statistical  analysis was performed using SPSS 17.0 for Windows.
All variables except TBARS and TRAP were normally distributed;
the results were represented as the mean ± standard deviation (SD)
or as percentages (%), as indicated. As TBARS and TRAP were not
normally distributed, the values were squared before parametric
tests. Associations between categorical variables were checked by
2 tests. For the comparisons of continuous variables among the
groups, we employed one-way analysis of covariance (ANCOVA),
and individual differences were assessed with the Tukey post-test
to adjust for multiple comparisons. An independent t-test was used
to detect differences among the variables. Pearson’s (r) correlation,
Spearman’s (ro) and partial correlation were used to identify cor-
relations among variables. P values < 0.05 (two-tailed values) were
considered to be statistically signiﬁcant.
3. Results
In total, 42 subjects with SZ on a HD and 54 subjects with
SZ on a RD without any nutritional orientation were included.
All subjects were sedentary and refrained from engaging in any
speciﬁc physical activities. The characteristics of patients with
and without nutritional orientation are summarized in Table 1.
The HD and RD subjects were similar in terms of gender. How-
ever, these two groups were different in terms of age distribution
(HD subjects were slightly older) and general psychopathol-
ogy (HD subjects had lower BPRS scores, increased frequency
of hyperglycemic and metabolic syndromes, and increased use
of clozapine (Cloz) compared to RD subjects). Table 2 shows
the differences in nutrients between the HD and RD, as an
example.
Serum TRAP levels were lower in HD compared to RD after
adjusting for BMI, age, the Cloz dose and BPRS (0.0017 ± 0.00036
and 0.0023 ± 0.00124, respectively, p = 0.022). Serum TBARS lev-
els were lower in HD subjects than in RD subjects (590.18 ± 85.09
and 516.63 ± 164.16, respectively, p = 0.023). TAR levels were sim-
ilar between both groups (23.42 ± 5.46 in HD and 23.56 ± 5.99 in
K. Zortea et al. / Neuroscience Letters 512 (2012) 43– 47 45
Table 1
Characteristics of subjects with schizophrenia in hypocaloric and regular diet.
Groupa
Characteristics Hypocaloric diet
(n  = 42)
Regular  diet
(n  = 54)
p value
Male sex – no. (%)b 30 (71.00) 38 (70.00) 0.923
Age – yearsc 40.93 ± 10.37 35.89 ± 9.23 0.014
Smoking  – no. (%)b 13 (32.50) 17 (32.10) 0.570
Age of onset of the diseasec 22.24 ± 9.36 20.27 ± 6.84 0.306
Length of illness – yearsc 18.85 ± 9.62 15.43 ± 10.64 0.143
Dose of antipsychotics in
mg/dayc,d
587.25 ± 280.23 616.42 ± 419.69 0.704
Clozapine use – no. (%)b 32 (76.20) 24 (44.40) 0.002
Clozapine dose in mg/dayc 425.64 ± 291.74 267.54 ± 330.51 0.018
BPRS  scorec 14.07 ± 8.96 21.03 ± 12.37 0.004
Weight in kgc 79.50 ± 18.07 78.03 ± 15.94 0.675
BMIc 27.81 ± 5.99 26.66 ± 4.72 0.298
Hyperglycemia – no. (%)b 24 (61.00) 15 (38.50) 0.001
High blood pressure – no.
(%)b
19 (45.23) 19 (35.18) 0.084
Dyslipidemia – no. (%)b 25 (44.60) 31 (55.40) 0.650
Metabolic Syndrome – no.
(%)b
22 (59.50) 15 (40.50) 0.010
Length of hypocaloric diet
in  monthsc
46.09 ± 25.73 NA NA
TRAPe,f 0.0017 ± 0.00036 0.0023 ± 0.00124 0.022
TARe 23.42 ± 5.46 23.56 ± 5.99 0.230
TBARS in nmol MDA/mg
proteine,f
590.18 ± 85.09 516.63 ± 164.16 0.023
BPRS (brief psychiatry rating scale); BMI  (body mass index); TRAP (total
radical-trapping antioxidant parameter); TAR (total antioxidant reactivity); TBARS
(thiobarbituric acid reactive species); MDA  (malondialdehyde). NA (not applicable);
SD (standard deviation).
a Columns show the mean ± SD for all categories except male sex, smoking,
clozapine  use, hyperglycemia, high blood pressure, dyslipidemia, and metabolic
syndrome.
b Chi-square test.
c Unpaired t test.
d Dose equivalent to chlorpromazine in mg/day.
e Analysis of covariance (ANCOVA) adjusted to the age (in years), BPRS, clozapine
dose  and BMI. Tukey post-test was  employed if the ANCOVA was signiﬁcant.
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Fig. 1. Box plot of serum total reactive antioxidant potential (TRAP) levels in sub-
jects with schizophrenia following a hypocaloric diet (n = 42) or regular diet (n = 54).
(TBARS) in patients with HD than in those with RD. The inverse
correlation between TRAP and TBARS levels may  reﬂect bio-
chemical consequences of body defenses (decreased antioxidant
defenses/TRAP leads to increased lipid peroxidation/TBARS).f As TBARS and TRAP were not normally distributed, they were square root-
ransformed  to be suitable for parametric analysis.
D, p = 0.23) (Table 1, Figs. 1–3). Adjustment for confounding vari-
bles failed to reveal an effect of comorbidities on TRAP and TBARS
evels.
There was a positive correlation between TRAP and TBARS
n the HD and RD groups (ro = 0.49, p < 0.001) that remained
igniﬁcant after adjustment for BMI  and the Cloz dose (partial corre-
ation = 0.42, p < 0.001). Illness and diet duration was  not correlated
o OS measures (TRAP, TBARS, and TAR) in the overall sample pop-
lation or in the HD and RD groups after adjustment for BMI  and
he Cloz dose (data not shown).
able 2
haracteristics of hypocaloric and regular diets.
Hypocaloric diet Regular diet
Total calories (kcal) 1509 2308
Carbohydrate – % (g) 60 (226) 54 (312)
Fat – % (g) 16 (27) 19 (49)
Protein – % (g) 23 (87) 26 (150)
Purine (mg) 384.82 610.32
Uric acid (mg) 320.78 536.10
Fiber (g) 25.5 36.99
Omega-3 (g) 0.34 0.61
Vitamin E (mg) 14.03 19.49
Ascorbic acid (mg) 138.55 192.39
Beta-carotene (mcg) 6856.78 6912.95
Selenium (mcg) 0.52 0.52
Zinc (mg) 18.78 30.88*p = 0.022 for hypocaloric diet vs. no hypocaloric diet (one-way ANCOVA with Tukey
post-test). Because TRAP was not normally distributed, it was square-root trans-
formed to be suitable for parametric analysis.
4. Discussion
To our knowledge, this is the ﬁrst study evaluating the
differences of OS parameters among schizophrenics under dif-
ferent diets (HD and RD), despite several studies on the role
of oxidative injury in SZ course and outcome. Although sub-
stantial evidence supports a weight loss effect induced by
lifestyle modiﬁcation strategies in the general population, this
effect has not been adequately studied in SZ [10]. One study
revealed the positive effect of a group-based, lifestyle intervention
program on BMI  in middle-aged and older SZ patients but failed to
assess OS parameters [14].
Our  naturalistic study in chronic SZ patients revealed reduced
antioxidant defenses (TRAP) and increased lipid peroxidationFig. 2. Box-plot of serum thiobarbituric acid reactive species (TBARS) levels in nmol
MDA/mg protein in subjects with schizophrenia on hypocaloric diet (n = 42) or reg-
ular diet (n = 54). *p = 0.023 for hypocaloric diet vs. no hypocaloric diet (one-way
ANCOVA  with Tukey post-test). As TBARS was not normally distributed, this vari-
able was square-root transformed to be suitable for parametric analysis (the graph
shows the data prior to transformation).
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Fig. 3. Serum total antioxidant reactivity (TAR) levels in subjects with schizophrenia
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ean  and 95% conﬁdence interval (95% CI) of the mean. *p = 0.23 for hypocaloric
iet  vs. no hypocaloric diet (one-way ANCOVA with Tukey post-test).
imilarly, differences in TAR levels between HD and RD subjects
uggest that HD may  decrease the amount of antioxidants (mea-
ured by TRAP) without inﬂuencing the quality of antioxidants
measured by TAR).
TAC  evaluates non-enzymatic antioxidants such as urate
35–65%), serum proteins (10–50%), ascorbate (0–24%), and vita-
in E (5–10%) [23]. Liposoluble vitamins such as vitamin E and
eta-carotene are inﬂuenced by lipid concentrations. A HD with
ecreased fat intake may  reduce liposoluble vitamins bioavailabil-
ty, thereby decreasing TAC.
The RD subjects without hypocaloric restrictions indicated a
igher protein intake compared to HD subjects (Table 2). The
ecreased protein consumption was expected in the HD and usu-
lly includes a decreased consumption of purine, uric acid and
ssential amino acids compared to diets without caloric restric-
ions. Additionally, several substances and proteins are affected by
ietary restrictions. One is urate, a product of protein metabolism,
hich also serves as a water-soluble antioxidant and an important
eterminant of TRAP (35–65%) [23]. Furthermore, protein thiols
re directly involved in cellular defense mechanisms against oxi-
ants [15]. Additionally, glutathione and albumin are also involved
n body defenses. Glutathione is an important intracellular pep-
ide with multiple functions, ranging from antioxidant defense to
he modulation of cell proliferation [13]. Albumin is considered
he major circulating antioxidant in serum [15]. These mechanisms
nd substances must be considered when interpreting the ﬁndings,
s they may  inﬂuence increased TRAP levels observed in RD sub-
ects compared to HD subjects following recommended nutritional
uidelines for at least 24 weeks.
Because this cross-sectional study assessed the effects of
ypocaloric diet prescription for a minimum of six months, it is not
ossible to draw conclusions on whether the OS changes occurred
t the beginning or end of dietary treatment. Additional studies
re necessary to understand the time-dependent response of a
ypocaloric diet on metabolism. We  expect early changes because
everal antioxidants, such as vitamin C and beta-carotene, typically
espond within the ﬁrst two weeks to changes in the dietary intake
f antioxidants [25]. Furthermore, the effect may  oscillate with time
ecause several other substances affected by caloric restriction can
lso inﬂuence oxidative processes and defenses. For example, uric
cid increases in the beginning of a dietary treatment and returns
o baseline levels after long-term dietary intervention [9].
In  a recent pilot study, we showed signiﬁcant weight loss and
igniﬁcantly decreased BMI  in patients with SZ, supporting theetters 512 (2012) 43– 47
importance  of a nutritional intervention and providing initial evi-
dence that treatment adherence and weight loss can be attained
and sustained among patients with SZ [27].
The aforementioned evidence must be considered in light of
some limitations: the study used a cross-sectional design with
naturalistic group allocation; a control group without SZ was not
included; the higher prevalence of clinical conditions related to
increased OS, such as the hyperglycemic and metabolic syndrome
evidenced by the HD group, could be partially responsible for the
differences due to a confusion bias.
5. Conclusion
In conclusion, subjects with SZ eating a HD for at least 24
weeks showed decreased serum TRAP levels and increased serum
TBARS levels; TBARS levels most likely increase following a bio-
chemical reaction with TRAP. Despite decreased TRAP levels in the
hypocaloric diet, no difference in TAR levels were found, suggesting
that the quality of antioxidants was not altered. Initially, the results
may be viewed as contrary to the expected effect of such a diet and
appear to suggest the detrimental effects of a hypocaloric diet on
oxidative patterns. However, a careful analysis of the data can pro-
vide arguments in favor of this intervention. The balance may be
more complicated and may  reﬂect several alternative processes.
First, intrinsic factors related to antioxidants may  explain this phe-
nomenon. TRAP is non-enzymatic and is reﬂected as a pool of urate
and proteins and, to a lesser extent, ascorbate and vitamin E; these
TRAP characteristics could reﬂect reduced protein intake affect-
ing oxidative defenses. Extrinsic factors related to the magnitude
of caloric intake, the bioavailability of nutrients, the confounding
effect of comorbidities, or the length of diet may  also explain the
results. To increase the knowledge of the interaction of these dif-
ferent factors over antioxidant defenses, more detailed studies are
needed to focus on the role of protein intake on the OS parameters
in SZ.
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